163 related articles for article (PubMed ID: 34992356)
1. Lung Function and Health Status in Individuals with Severe Alpha-1-Antitrypsin Deficiency at the Age of 42.
Schramm GR; Mostafavi B; Piitulainen E; Wollmer P; Tanash HA
Int J Chron Obstruct Pulmon Dis; 2021; 16():3477-3485. PubMed ID: 34992356
[TBL] [Abstract][Full Text] [Related]
2. Health status and lung function in the Swedish alpha 1-antitrypsin deficient cohort, identified by neonatal screening, at the age of 37-40 years.
Piitulainen E; Mostafavi B; Tanash HA
Int J Chron Obstruct Pulmon Dis; 2017; 12():495-500. PubMed ID: 28203073
[TBL] [Abstract][Full Text] [Related]
3. Lung function and CT lung densitometry in 37- to 39-year-old individuals with alpha-1-antitrypsin deficiency.
Mostafavi B; Diaz S; Piitulainen E; Stoel BC; Wollmer P; Tanash HA
Int J Chron Obstruct Pulmon Dis; 2018; 13():3689-3698. PubMed ID: 30510411
[TBL] [Abstract][Full Text] [Related]
4. The Swedish α1-Antitrypsin Screening Study: Health Status and Lung and Liver Function at Age 34.
Tanash HA; Nystedt-Düzakin M; Montero LC; Sveger T; Piitulainen E
Ann Am Thorac Soc; 2015 Jun; 12(6):807-12. PubMed ID: 25803183
[TBL] [Abstract][Full Text] [Related]
5. PiSZ alpha-1 antitrypsin deficiency (AATD): pulmonary phenotype and prognosis relative to PiZZ AATD and PiMM COPD.
Green CE; Vayalapra S; Hampson JA; Mukherjee D; Stockley RA; Turner AM
Thorax; 2015 Oct; 70(10):939-45. PubMed ID: 26141072
[TBL] [Abstract][Full Text] [Related]
6. Lung Function and CT Densitometry in Subjects with alpha-1-Antitrypsin Deficiency and Healthy Controls at 35 Years of Age.
Piitulainen E; Montero LC; Nystedt-Düzakin M; Stoel BC; Sveger T; Wollmer P; Tanash HA; Diaz S
COPD; 2015 Apr; 12(2):162-7. PubMed ID: 25280185
[TBL] [Abstract][Full Text] [Related]
7. Lung function in 30-year-old alpha-1-antitrypsin-deficient individuals.
Bernspång E; Wollmer P; Sveger T; Piitulainen E
Respir Med; 2009 Jun; 103(6):861-5. PubMed ID: 19181511
[TBL] [Abstract][Full Text] [Related]
8. Deterioration of quality of life is associated with the exacerbation frequency in individuals with alpha-1-antitrypsin deficiency - analysis from the German Registry.
Bernhard N; Lepper PM; Vogelmeier C; Seibert M; Wagenpfeil S; Bals R; Fähndrich S
Int J Chron Obstruct Pulmon Dis; 2017; 12():1427-1437. PubMed ID: 28553095
[TBL] [Abstract][Full Text] [Related]
9. Decreased Risk of Ischemic Heart Disease in Individuals with Severe Alpha 1-Antitrypsin Deficiency (PiZZ) in Comparison with the General Population.
Tanash H; Ekström M; Basil N; Rönmark E; Lindberg A; Piitulainen E
Int J Chron Obstruct Pulmon Dis; 2020; 15():1245-1252. PubMed ID: 32606637
[TBL] [Abstract][Full Text] [Related]
10. Z-alpha1-antitrypsin polymers and small airways disease: a new paradigm in alfa-1 anti-trypsin deficiency-related COPD development?
Pini L; Tiberio L; Arici M; Corda L; Giordani J; Bargagli E; Tantucci C
Monaldi Arch Chest Dis; 2021 Jun; 91(4):. PubMed ID: 34468105
[TBL] [Abstract][Full Text] [Related]
11. Decline in FEV
Hiller AM; Piitulainen E; Jehpsson L; Tanash H
Int J Chron Obstruct Pulmon Dis; 2019; 14():1075-1083. PubMed ID: 31213789
[No Abstract] [Full Text] [Related]
12. Intensive smoking diminishes the differences in quality of life and exacerbation frequency between the alpha-1-antitrypsin deficiency genotypes PiZZ and PiSZ.
Bernhard N; Lepper PM; Vogelmeier C; Seibert M; Wagenpfeil S; Bals R; Fähndrich S
Respir Med; 2017 Sep; 130():1-8. PubMed ID: 29206626
[TBL] [Abstract][Full Text] [Related]
13. The Clinical Course of Severe Alpha-1-Antitrypsin Deficiency in Patients Identified by Screening.
Hiller AM; Piitulainen E; Tanash H
Int J Chron Obstruct Pulmon Dis; 2022; 17():43-52. PubMed ID: 35023912
[TBL] [Abstract][Full Text] [Related]
14. Exacerbations and duration of smoking abstinence are associated with the annual loss of FEV
Fähndrich S; Bernhard N; Lepper PM; Vogelmeier C; Seibert M; Wagenpfeil S; Bals R
Respir Med; 2017 Aug; 129():8-15. PubMed ID: 28732839
[TBL] [Abstract][Full Text] [Related]
15. The Clinical Profile of Subjects Included in the Swedish National Register on Individuals with Severe Alpha 1-Antitrypsin deficiency.
Piitulainen E; Tanash HA
COPD; 2015 May; 12 Suppl 1():36-41. PubMed ID: 25938290
[TBL] [Abstract][Full Text] [Related]
16. CT lung densitometry in young adults with alpha-1-antitrypsin deficiency.
Bernspång E; Diaz S; Stoel B; Wollmer P; Sveger T; Piitulainen E
Respir Med; 2011 Jan; 105(1):74-9. PubMed ID: 20674322
[TBL] [Abstract][Full Text] [Related]
17. An association between plasma levels of α2-macroglobulin and α1-antitrypsin in PiMM and PiZZ individuals differing in COPD presentation.
Lechowicz U; Martinez-Delgado B; Liu B; Wrenger S; Rozy A; Zdral A; DeLuca DS; Welte T; Janciauskiene S; Chorostowska-Wynimko J
Clin Biochem; 2024 Apr; 126():110736. PubMed ID: 38428450
[TBL] [Abstract][Full Text] [Related]
18. Survival in individuals with severe alpha 1-antitrypsin deficiency (PiZZ) in comparison to a general population with known smoking habits.
Tanash HA; Ekström M; Rönmark E; Lindberg A; Piitulainen E
Eur Respir J; 2017 Sep; 50(3):. PubMed ID: 28889108
[TBL] [Abstract][Full Text] [Related]
19. Effect of age and occupational exposure to airway irritants on lung function in non-smoking individuals with alpha 1-antitrypsin deficiency (PiZZ).
Piitulainen E; Tornling G; Eriksson S
Thorax; 1997 Mar; 52(3):244-8. PubMed ID: 9093340
[TBL] [Abstract][Full Text] [Related]
20. Unique and shared systemic biomarkers for emphysema in Alpha-1 Antitrypsin deficiency and chronic obstructive pulmonary disease.
Serban KA; Pratte KA; Strange C; Sandhaus RA; Turner AM; Beiko T; Spittle DA; Maier L; Hamzeh N; Silverman EK; Hobbs BD; Hersh CP; DeMeo DL; Cho MH; Bowler RP
EBioMedicine; 2022 Oct; 84():104262. PubMed ID: 36155958
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
